Business Context and Reporting Period
Company: Coherus BioSciences, Inc. (formerly Coherus Oncology, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: May 15, 2023
Event: Entry into a Material Definitive Agreement regarding the reduction of an "at-the-market" (ATM) equity offering program.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. It specifically addresses the capacity for future equity issuance:
- Original ATM Program Cap: $150.0 million
- Reduction Amount: $86.25 million
- New ATM Program Cap: $63.75 million
- Agent: Cowen and Company, LLC
Material Changes
On May 15, 2023, the Company executed Amendment No. 1 to its Sales Agreement with Cowen. This amendment reduced the aggregate offering price available under the ATM program from $150.0 million to $63.75 million. The filing text does not provide a prior comparable period for financial performance metrics as this is a transactional report rather than a periodic financial statement.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding future financial performance or strategic direction beyond the execution of the ATM reduction.
Risks and Contingencies: The filing notes that the description of the amendment is qualified in its entirety by reference to the full text of Amendment No. 1, which will be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2023. No specific risks or contingencies are detailed in this document.
Key Facts for Investor Verification
- Verify the full text of Amendment No. 1 to the Sales Agreement in the upcoming Form 10-Q for the quarter ended June 30, 2023.
- Confirm the remaining $63.75 million cap under the ATM program and any subsequent sales activity.
- Review the Company's cash position and liquidity needs to understand the rationale behind reducing the ATM capacity.
- Check for any concurrent announcements regarding capital raising or strategic shifts that may have prompted this reduction.